RCEL
AVITA Medical, Inc.
Set alert
15.65 USD -1.06 -6.34%
15.24 Day range 16.60
3.27 52-week range 16.71
- YTD
- +353.62%
- 1 year
- +326.43%
- Open
- 16.54
- Prev close
- 16.71
- Mkt cap
- 484.01M
- Vol
- 597.05K
- Avg vol
- 482.35K
- EPS
- -1.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.24
- High
- 16.60
- Forward P/E
- -14.33
- Beta
- 1.54
- Short ratio
- 10.24
- Inst. own
- 23.45%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.87
- 200-d avg
- 10.61
- 1y target
- 16.81
Key statistics
- Market cap
- 308.06M
- Enterprise value
- 309.80M
- Trailing P/E
- 0.00
- Forward P/E
- -14.33
- PEG ratio
- 0.00
- Price / sales
- 5.13
- Price / book
- 25.21
- EPS (TTM)
- -2.23
- Beta
- 1.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -95.47%
- Revenue (TTM)
- 60.04M
- Revenue growth
- 43.20%
- Free cash flow
- -33.68M
- Total cash
- 44.41M
- Total debt
- 45.63M
- Return on equity
- -152.44%
- Shares outstanding
- 26.22M
- Short % of float
- 4.49%
- 50-day average
- 11.87
- 200-day average
- 10.61
Analyst view
Consensus: buy
Buy
Price target (mean) 16.81 +7.4% upside
Now 15.65
- Target (low)
- 11.38
- Target (mean)
- 16.81
- Target (high)
- 20.95
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.56534.
Financials — quick view
RCEL Revenue — quarterly 21.70M
RCEL Net income — quarterly -7.66M
RCEL EPS — quarterly -0.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.42 | -0.62 | -0.20 | -47.62% |
| Aug 8, 2024 | Jun 1, 2024 | -0.59 | -0.60 | -0.01 | -1.69% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.73 | -0.47 | -180.77% |
| Feb 22, 2024 | Dec 1, 2023 | -0.34 | -0.28 | +0.06 | +17.65% |
| Nov 9, 2023 | Sep 1, 2023 | -0.53 | -0.34 | +0.19 | +35.85% |
| Aug 10, 2023 | Jun 1, 2023 | -0.34 | -0.41 | -0.07 | -20.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Piper Sandler | reit | Neutral | Neutral |
| Aug 9, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| May 14, 2024 | Piper Sandler | down | Overweight | Neutral |
| May 14, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Apr 11, 2024 | BTIG | down | Buy | Neutral |
| Feb 23, 2024 | Piper Sandler | reit | Overweight | Overweight |
About AVITA Medical, Inc.
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- avitamedical.com
News
- AVITA Medical to Announce Third Quarter 2026 Financial Results
- BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
- AVITA Medical Q2 2026 Earnings Call Transcript
- Head-To-Head Comparison: Organigram Global (NASDAQ:OGI) versus Avita Medical (NASDAQ:RCEL)
- Leading Indicators For The October Breakout Cycle
- Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued
- NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL
- AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
- All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Your note
Sign in to keep a note on RCEL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.10% | 1,860,519 | 21.86M | Sep 29, 2024 |
| Vanguard Group Inc | 5.41% | 1,417,672 | 16.66M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.27% | 594,436 | 6.98M | Sep 29, 2024 |
| State Street Corporation | 1.98% | 519,997 | 6.11M | Sep 29, 2024 |
| Essex Investment Management Co LLC | 0.88% | 231,094 | 2.72M | Sep 29, 2024 |
| Northern Trust Corporation | 0.83% | 216,467 | 2.54M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.05% | 800,719 | 9.41M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.50% | 656,684 | 7.72M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.48% | 389,203 | 4.57M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.00% | 262,420 | 3.08M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.88% | 231,647 | 2.72M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.55% | 145,150 | 1.71M | Oct 30, 2024 |